According to Zhitong Finance App, Kunbo Medical-B (02216.HK) announced that on December 29, 2025, Broncus China Holding Corporation, a wholly-owned subsidiary of the company, plans to acquire 157,800 B-series preferred shares of Valgen Holding Corporation from Qiming Medical (Hong Kong) Co., Ltd., accounting for 1.05% of the target company's external shares issued on a comprehensive dilution and conversion basis as of the date of this announcement, at a total cost of US$15 million. Target Group is mainly engaged in providing system solutions for diseases such as mitral valve reflux and tricuspid valve reflux. Its products include the mitral valve repair device DragonFly™ (transfemoral route) and the tricuspid valve repair device DragonFly-TTM.

According to Zhitong Finance App, Kunbo Medical-B (02216.HK) announced that on December 29, 2025, Broncus China Holding Corporation, a wholly-owned subsidiary of the company, plans to acquire 157,800 B-series preferred shares of Valgen Holding Corporation from Qiming Medical (Hong Kong) Co., Ltd., accounting for 1.05% of the target company's external shares issued on a comprehensive dilution and conversion basis as of the date of this announcement, at a total cost of US$15 million. Target Group is mainly engaged in providing system solutions for diseases such as mitral valve reflux and tricuspid valve reflux. Its products include the mitral valve repair device DragonFly™ (transfemoral route) and the tricuspid valve repair device DragonFly-TTM.